1 |
A Post Marketing Study of the Safety, Tolerability, and Pharmacokinetics of TPOXX In Adult Subjects Weighing More Than 120 KG |
Completed |
NCT04392739 |
Phase 4 |
Tpoxx |
2 |
Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) |
Recruiting |
NCT02443623 |
Phase 4 |
|
3 |
A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects |
Not yet recruiting |
NCT04485039 |
Phase 4 |
TPOXX |
4 |
An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects |
Completed |
NCT02474589 |
Phase 3 |
tecovirimat |
5 |
A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects |
Completed |
NCT01913353 |
Phase 3 |
|
6 |
An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers |
Completed |
NCT01317238 |
Phase 3 |
smallpox vaccine CJ-50300 |
7 |
A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects |
Completed |
NCT01144637 |
Phase 3 |
|
8 |
An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers |
Completed |
NCT01056770 |
Phase 3 |
smallpox vaccine CJ-50300 |
9 |
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects |
Completed |
NCT03699124 |
Phase 3 |
|
10 |
Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers |
Completed |
NCT00607243 |
Phase 2, Phase 3 |
|
11 |
Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) |
Completed |
NCT01158157 |
Phase 3 |
|
12 |
An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo |
Active, not recruiting |
NCT02977715 |
Phase 3 |
|
13 |
A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers |
Unknown status |
NCT00103584 |
Phase 1, Phase 2 |
|
14 |
Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals |
Completed |
NCT00879762 |
Phase 2 |
Placebo |
15 |
ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes |
Completed |
NCT00133575 |
Phase 1, Phase 2 |
|
16 |
Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects |
Completed |
NCT00189956 |
Phase 2 |
|
17 |
The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination |
Completed |
NCT00053482 |
Phase 2 |
|
18 |
Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination |
Completed |
NCT00466245 |
Phase 2 |
MVA Smallpox vaccine;Placebo |
19 |
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination |
Completed |
NCT00189904 |
Phase 1, Phase 2 |
|
20 |
The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination |
Completed |
NCT00053495 |
Phase 2 |
|
21 |
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection |
Completed |
NCT02038881 |
Phase 2 |
|
22 |
A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNEâ„¢) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis |
Completed |
NCT00316602 |
Phase 2 |
|
23 |
A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. |
Completed |
NCT00316589 |
Phase 2 |
|
24 |
A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNEâ„¢) Smallpox Vaccine in 18-55 Year Old Healthy Subjects |
Completed |
NCT00316524 |
Phase 2 |
|
25 |
A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults |
Completed |
NCT00038987 |
Phase 1, Phase 2 |
|
26 |
Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults. |
Completed |
NCT00258947 |
Phase 2 |
|
27 |
A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus |
Completed |
NCT00063856 |
Phase 1, Phase 2 |
|
28 |
A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults |
Completed |
NCT00050505 |
Phase 2 |
|
29 |
A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults |
Completed |
NCT00026611 |
Phase 2 |
|
30 |
A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. |
Completed |
NCT00050518 |
Phase 2 |
|
31 |
Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults |
Completed |
NCT00437021 |
Phase 1, Phase 2 |
Placebo (subcutaneous);Placebo (scarification) |
32 |
A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults |
Completed |
NCT00032708 |
Phase 2 |
|
33 |
A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects |
Completed |
NCT01668537 |
Phase 2 |
|
34 |
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects |
Completed |
NCT00857493 |
Phase 2 |
|
35 |
A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery |
Completed |
NCT01827371 |
Phase 2 |
|
36 |
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees |
Completed |
NCT00686582 |
Phase 2 |
|
37 |
Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals |
Completed |
NCT00914732 |
Phase 2 |
|
38 |
Open Label, Dose Escalation and Age De-escalation for ChAdOx1 85A in Ugandan Adults and Adolescents, Followed by a Phase IIa Randomised, Open-label Trial Among Adolescents Comparing ChAdOx1 85A Prime Followed by MVA 85A Boost Versus BCG Re-vaccination. |
Recruiting |
NCT03681860 |
Phase 1, Phase 2 |
|
39 |
MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas |
Recruiting |
NCT04410874 |
Phase 1, Phase 2 |
|
40 |
The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study |
Terminated |
NCT00053508 |
Phase 2 |
|
41 |
MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization |
Completed |
NCT00565929 |
Phase 1 |
Placebo |
42 |
The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination |
Completed |
NCT00079820 |
Phase 1 |
|
43 |
A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults |
Completed |
NCT02743455 |
Phase 1 |
ISA-720 |
44 |
Evaluation of Human Immune Response to Smallpox Vaccine (Vaccinia Virus) |
Completed |
NCT00068198 |
Phase 1 |
|
45 |
A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®) |
Completed |
NCT00042094 |
Phase 1 |
|
46 |
Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years |
Completed |
NCT00189969 |
Phase 1 |
|
47 |
An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders |
Completed |
NCT00189917 |
Phase 1 |
|
48 |
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers |
Completed |
NCT00002261 |
Phase 1 |
|
49 |
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of MVA-BN in a Dose Response Regimen Followed by Administration of Dryvax in Healthy Adult Volunteers |
Completed |
NCT00082446 |
Phase 1 |
|
50 |
Randomized, Double Blind, Placebo Control Study to Evaluate the Safety and Immunogenicity of CJ-50300 in Healthy Volunteers : Phase I |
Completed |
NCT00336635 |
Phase 1 |
|